gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 29 Mar 2014.

Interleukin 6 receptor

IL-6R, interleukin-6 receptor, gp80, IL-6Ralpha
This gene encodes a subunit of the interleukin 6 (IL6) receptor complex. Interleukin 6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. The IL6 receptor is a protein complex consisting of this protein and interleukin 6 signal transducer (IL6ST/GP130/IL6-beta), a receptor subunit also shared by many other cytokines. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been reported. A pseudogene of this gene is found on chromosome 9.[provided by RefSeq, May 2011] (from NCBI)
Top mentioned proteins: Interleukin-6, NMDA receptor, CAN, V1a, STAT3
Papers using IL-6R antibodies
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Supplier
Sesti Giorgio, In PLoS ONE, 1997
... used anti-cytokines antibodies against IL-1ß, IL-6, TNFα, IFNγ, and anti-cytokine receptor antibodies against IL-1R1, IL-1R2, IL-6R, TNF-R1, IFN-Rα, IFN-Rß (Santa Cruz Biotechnology, Santa Cruz, CA); guinea ...
Papers on IL-6R
A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial.
New
Ravelli et al., Genova, Italy. In Arthritis Rheumatol, 31 Mar 2014
BACKGROUND/PURPOSE: A phase 3 trial (TENDER) demonstrated the efficacy of the interleukin-6 receptor inhibitor tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA) ().
A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH.
New
De Benedetti et al., Cincinnati, United States. In Arthritis Rheumatol, 31 Mar 2014
BACKGROUND/PURPOSE: The efficacy and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, were previously demonstrated at week 40 of CHERISH, a phase 3 trial in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA) ().
A171: tocilizumab dosing in juvenile idiopathic arthritis: optimizing for different juvenile idiopathic arthritis type and patient body weight.
New
Benedetti et al., Nutley, United States. In Arthritis Rheumatol, 31 Mar 2014
BACKGROUND/PURPOSE: Tocilizumab (TCZ), an interleukin-6 receptor (IL-6R) inhibitor, is effective in systemic and polyarticular juvenile idiopathic arthritis (sJIA, pJIA).
A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH.
New
De Benedetti et al., Genova, Italy. In Arthritis Rheumatol, 31 Mar 2014
BACKGROUND/PURPOSE: The phase 3 CHERISH trial demonstrated the efficacy of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA).
Multiple cytokine-producing testicular malignant lymphoma with clinical symptoms resembling infectious signs.
New
Hanafusa et al., Ōsaka, Japan. In Int J Immunopathol Pharmacol, Jan 2014
This is the first case report of testicular diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) immunostained for multiple cytokines and their receptors, which clearly demonstrates that tumor cells express multiple cytokines [interleukin-6 (IL-6) and granulocyte colony-stimulating factor (G-CSF)] and their receptors [IL-6 receptor (IL-6R) and G-CSF receptor (G-CSFR)].
Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities.
Review
New
Rose-John et al., Düsseldorf, Germany. In Semin Immunol, Jan 2014
A soluble form of the human IL-6R is generated by limited proteolysis and alternative splicing.
Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
New
Lensch et al., Wiesbaden, Germany. In Bmj Case Rep, Dec 2013
We present a 32-year-old female patient with fulminant neuromyelitis optica.
Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.
Review
New
Frampton, North Shore, New Zealand. In Paediatr Drugs, Dec 2013
Tocilizumab (RoActemra(®); Actemra(®)) is a recombinant humanized monoclonal antibody that acts as an interleukin-6 receptor antagonist.
Metalloproteinases and their natural inhibitors in inflammation and immunity.
Review
New
Impact
Weiss et al., Toronto, Canada. In Nat Rev Immunol, Sep 2013
Together with their endogenous inhibitors TIMPs (tissue inhibitor of metalloproteinases), these enzymes regulate signalling downstream of the tumour necrosis factor receptor and the interleukin-6 receptor, as well as that downstream of the epidermal growth factor receptor and Notch, which are all pertinent for inflammatory responses.
Predicting high risk disease using serum and DNA biomarkers.
Review
New
Nam et al., Toronto, Canada. In Curr Opin Urol, May 2013
RECENT FINDINGS: There is increasing evidence that serum biomarkers human Kallikrein 2, early prostate cancer antigen, urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor, transforming growth factor-β1 and interleukin-6/interleukin-6 receptor and genetic biomarkers BRCA1 and BRCA2, Phosphatase and tensin homolog, cellular myelocytomatosis oncogene and NKX3.1 may predict for aggressive high grade disease and are identifiable early in prostate carcinogenesis.
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
Impact
PRCSG et al., Roma, Italy. In N Engl J Med, 2013
METHODS: We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti-interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the weight was ≥30 kg or 12 mg per kilogram if the weight was <30 kg) or placebo given intravenously every 2 weeks during the 12-week, double-blind phase.
[Indications and efficacy of biologics in inflammatory arthritis].
Review
Combe, Montpellier, France. In Bull Acad Natl Med, 2012
Later, rituximab, an anti-CD20 B lymphocyte antibody ; abatacept, which inhibits the T cell co-stimulatory CD28-CD80 pathway ; and tocilizumab, an interleukin-6 receptor inhibitor, were launched in rheumatoid arthritis.
The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma.
GeneRIF
National Heart et al., Winston-Salem, United States. In J Allergy Clin Immunol, 2012
The IL6R coding SNP rs2228145 (Asp358Ala) is a potential modifier of lung function in subjects with asthma and might identify subjects at risk for more severe asthma.
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
GeneRIF
Shin et al., South Korea. In Int J Oncol, 2012
IL-6R is present in cancer stem cells and has an important role in the proliferation
Interleukin-6 receptor α is co-localised with melanin-concentrating hormone in human and mouse hypothalamus.
GeneRIF
Jansson et al., Göteborg, Sweden. In J Neuroendocrinol, 2012
Il6r alpha is co-localized with melanin-concentrating hormone in mouse hypothalamus.
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Impact
GeneRIF
Danesh et al., In Lancet, 2012
We assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6.
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Impact
Casas et al., In Lancet, 2012
Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation.
Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation.
GeneRIF
Banas et al., Regensburg, Germany. In Cytokine, 2012
Elevated urinary concentrations of IL6, sIL6R, TNFR1 and sVCAM-1 clearly indicate an early acute transplant rejection.
Therapeutic targeting of the interleukin-6 receptor.
Review
Impact
Kishimoto et al., Ōsaka, Japan. In Annu Rev Pharmacol Toxicol, 2011
Interleukin (IL)-6 is a typical cytokine featuring redundancy and pleiotropic activity.
Identification of IL6R and chromosome 11q13.5 as risk loci for asthma.
Impact
GeneRIF
Australian Asthma Genetics Consortium et al., Brisbane, Australia. In Lancet, 2011
associated with asthma risk
share on facebooktweetadd +1mail to friends